# Drug Pricing **Drug pricing** is the third leg of the [[Healthcare Industry Ecosystem]] — alongside hospital ownership (who owns the beds) and managed care (who controls the money), drug pricing is the question of **why Americans pay more for medicines than anyone else on earth, and who captures the difference.** The U.S. has no single price for a drug; it has a chain of prices, each set by a different actor with its own incentive to obscure the next. ## The Money Flow (and Why No One Will Show It) A prescription drug's price is built up — and hidden — across a supply chain: 1. **Manufacturer** sets a **[[List Price]]** (the WAC, or wholesale acquisition cost) — the headline number that almost no one actually pays. 2. **[[Pharmacy Benefit Managers]]** (the Big Three — CVS Caremark, Express Scripts, OptumRx) negotiate **[[Drug Rebate]]s** off that list price in exchange for [[Formulary]] placement. The rebates flow back upstream and are largely invisible to the patient. 3. **Insurer / plan** sets the patient's cost-sharing — often a percentage of the *list* price, not the rebated net price, so patients can pay more when rebates are bigger. 4. **Pharmacy** dispenses; in [[Medicaid]] managed care the PBM may pocket the gap between what it bills the plan and what it pays the pharmacy via **[[Spread Pricing]]**. 5. **Patient** pays at the counter — the only actor who sees none of the negotiation that set their price. The gap between list and net price is the central fact of U.S. drug pricing: it is where the rebate economy lives, and why [[Big Pharma]] and the PBMs spend so heavily blaming each other rather than disclosing it. ## Why U.S. Prices Are the Highest - **No unified negotiator.** Until recently the federal government was barred from negotiating Medicare drug prices — the [[Medicare Part D]] "non-interference" clause. Other wealthy countries negotiate as single payers; the fragmented U.S. system does not. - **Patent and exclusivity gaming.** Manufacturers extend monopolies through **[[Patent Evergreening]]** (thickets of secondary patents) and **[[Pay-for-Delay]]** settlements that keep generics and **[[Biosimilar]]s** off the market. - **The rebate trap.** PBM rebates reward *higher* list prices, not lower ones — a structural incentive against affordability. ## The Policy Levers (2022–2026) - **[[Drug Price Negotiation]] (IRA).** The [[Inflation Reduction Act]] finally let Medicare negotiate. The first 10 negotiated prices took effect **January 2026** (a minimum 38% off 2023 list prices); a second cohort of 15 drugs — including the Ozempic/Wegovy GLP-1 family — was negotiated for **2027**, with 20 more per year from 2029. It also capped insulin at $35/month and Part D out-of-pocket costs. - **[[Most-Favored-Nation Drug Pricing Deals]] + TrumpRx.** The Trump administration pursued a parallel, executive-driven track: bilateral "most-favored-nation" deals with manufacturers (Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, Regeneron, and others) and the **TrumpRx.gov** direct-to-consumer platform launched February 2026, offering MFN-aligned prices (e.g., GLP-1 vials around $350/month). Critics note these deals run alongside — and sometimes against — the IRA's statutory negotiation. - **PBM reform.** The February 2026 PBM reform law targeted [[Spread Pricing]] and rebate opacity — the deflection [[Big Pharma]] lobbied *for*, since it left manufacturer list pricing untouched. ## Why It Matters Here Drug pricing is the most bipartisan health grievance and the one where the [[MAHA]] right, populist left, and the Trump administration all claim the mantle of reform while pursuing very different mechanisms. It is also the cleanest case of [[Corporate Capture]]: the same vertically integrated conglomerates ([[UnitedHealth Group]], [[CVS Health]], [[Cigna]]) that insure patients also own the PBMs that set what those patients pay. See [[Big Pharma]] (manufacturers), [[Pharmacy Benefit Managers]] (middlemen), and the [[Healthcare Industry Ecosystem]] (the whole map). ## See also - [[Insulin and the Politics of Drug Pricing]] — a century-old drug priced as a luxury, and the fight over capping it